Novel insights in intestinal and hepatic fructose metabolism: from mice to men.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical studies without systematic methodology
PubMed 35838297 · doi:10.1097/MCO.0000000000000853
What was done
This narrative review synthesized evidence from animal models, epidemiological studies, and preliminary human clinical trials investigating the intestinal and hepatic pathways of fructose metabolism and their contributions to obesity, de novo lipogenesis, and cardiometabolic disease.
What was found
The abstract reports no numerical data or effect sizes. Preclinical findings indicate that fructose impairs gut microbiome composition and intestinal barrier integrity while elevating intestinal absorption capacity through fructose 1-phosphate (F1-P) signaling. In humans, fructose intake from sugar-sweetened beverages stimulates de novo lipogenesis and intrahepatic lipid accumulation. In addition, aldolase B deficiency (characterized by F1-P accumulation) associates with increased intrahepatic lipids, whereas phase II trials show that ketohexokinase inhibition reduces intrahepatic lipid content.
Why it matters
The review outlines how both intestinal and hepatic handling of fructose contribute to liver fat accumulation, supporting public health interventions targeting sugar-sweetened beverages as well as therapeutic development of ketohexokinase inhibitors.
Limits
As a narrative review, it lacks systematic search protocols, defined study inclusion criteria, and formal quality assessments. No specific sample sizes, demographic characteristics, or quantitative effect sizes are provided in the abstract, and rodent metabolic mechanisms cannot be directly assumed to fully translate to human physiology.
Cited by
- supports When the liver metabolizes fructose, it stimulates de novo lipogenesis and fat production.